Immunogenicity Assessment Advisor
Assess immunogenicity risk, design ADA detection strategies, and generate regulatory reports
What You Can Do
You can conduct molecule-specific immunogenicity risk stratification, design ADA detection strategies with assay platform selection and bridging validation, and interpret complex immunogenicity data for clinical and regulatory communication. The skill guides you through ICH S6, FDA 2014 guidance, and EMA CHMP expectations to translate ADA prevalence, titer, and neutralizing capacity into actionable clinical risk assessments and submission-ready reports.
Features
evaluate immunogenicity hazard by molecule class (protein, mAb, conjugate, ADC), manufacturing process, and patient population before study initiation
select screening and confirmatory platforms, establish bridging approaches, and define sensitivity requirements aligned with clinical needs
contextualize prevalence, titer kinetics, and neutralizing antibody capacity within clinical safety signals and PK/PD relationships
structure immunogenicity sections for clinical overviews, safety updates, and integrated summaries compliant with FDA/EMA submission standards
apply bioanalytical method validation principles specific to ADA detection (specificity, sensitivity, cut points, incubation conditions)
recommend sampling frequency, time points, and patient subgroup analysis strategies for immunogenicity monitoring
assess immunogenicity profile differences between manufacturing changes, formulations, or clinical populations
Example Output
Example 1: Risk Assessment Output
Molecule: Recombinant human IL-2 fusion protein
Immunogenicity Risk Level: MODERATE-HIGH
Key Risk Factors:
- Novel fusion architecture (increased immunogenicity vs. native IL-2)
- Subcutaneous administration (higher ADA risk than IV)
- Chronic dosing (repeated exposure)
Recommended Strategy:
- Sensitive bridging ELISA + confirmatory assay (neutralization)
- Sampling: baseline, weeks 2, 4, 8, 12, EOT, follow-up
- Pre-dose and post-dose sampling recommended
- Patient subgroup analysis: prior IL-2 exposure vs. naïve
Example 2: ADA Detection Strategy Output
Recommended Two-Tier Assay:
- Screening: Electrochemiluminescence (ECL) platform — high sensitivity for low-titer ADA
- Confirmation: Surface plasmon resonance (SPR) — specificity and kinetic data
Assay Characteristics:
- Screening cut point: 0.15 μg/mL (based on 1.645 × SD of negative control)
- Confirmatory cut point: 0.08 μg/mL
- Expected sensitivity: 98% at 0.5 μg/mL equivalence
- Bridging validation: correlation R² > 0.95 with legacy ELISA
Example 3: Regulatory Reporting
ADA Prevalence Summary:
- Overall: 12/89 subjects (13.5%) developed treatment-emergent ADA
- Median titer: 3.2 μg/mL (range: 0.08–18.4)
- Neutralizing capacity: 8/12 ADA+ subjects (67%) showed in vitro neutralization
- Clinical impact: No dose adjustment or discontinuation due to ADA alone; no correlation with PK loss of response
What's Included
- SKILL.md: complete instruction file with risk stratification framework, assay selection logic, and regulatory guidance context
- Immunogenicity Risk Assessment Template: molecule-class-specific checklist for hazard evaluation and strategy recommendation
- ADA Assay Strategy Worksheet: platform selection matrix, bridging validation checklist, and cut-point justification framework
- Data Interpretation Guide: prevalence categorization, titer kinetics interpretation, and clinical correlation decision tree
- Regulatory Submission Checklist: FDA/EMA section-by-section requirements for clinical overview, safety update, and integrated immunogenicity summary
Who It's For
- Bioanalytical scientists — designing ADA detection strategies and validating immunogenicity assays in discovery/development
- Clinical development scientists — interpreting immunogenicity data, assessing clinical risk, and recommending dose/monitoring adjustments
- Regulatory affairs specialists — preparing immunogenicity sections of CTD modules, clinical overviews, and safety updates for FDA/EMA submissions
- Program managers — evaluating immunogenicity risk at program inception and accelerating timelines through upfront strategy clarity
- Quality/CMC scientists — understanding manufacturing changes' immunogenicity impact and supporting comparability studies
Best For
- Immunogenicity risk assessment for new biopharmaceutical programs (proteins, mAbs, conjugates, ADCs)
- ADA assay platform selection and bridging strategy design
- Clinical immunogenicity study report preparation and data interpretation
- Regulatory submission drafting (clinical overview, integrated safety summary, specific immunogenicity sections)
- Post-approval immunogenicity signal investigation and manufacturing change impact assessment
- Cross-functional immunogenicity alignment meetings with clinical, regulatory, and CMC teams
You might also like
You can design and execute bioanalytical method validations aligned with FDA Guidance for Industry and ICH guidelines, interpret complex validation data against regulatory acceptance criteria, and systematically troubleshoot analytical failures to identify root causes and corrective actions. This skill accelerates validation timelines by 20–30%, minimizes regulatory rework, and provides structured decision trees for problems that typically require expert consultation.
by kody-wClaude reviews your injection mold, stamping die, or precision tool designs for manufacturability, cost reduction opportunities, and tolerance optimization. You provide CAD specifications, material details, and production volume—Claude identifies specific design modifications, material alternatives, and tolerance adjustments that reduce tooling complexity and unit costs without compromising performance.
by kody-w
This skill evaluates your current workstation setup, identifies ergonomic risks, and delivers actionable recommendations to reduce strain and injury. It analyzes factors like monitor height, desk ergonomics, seating, keyboard positioning, and lighting to create a personalized improvement plan that you can implement immediately.
by kody-w
Systematically evaluate ingredient compatibility against your active pharmaceutical ingredients, predict formulation behavior and stability risks, and troubleshoot phase separation, incompatibility, and irritation issues in real time. Generate ICH-aligned stability protocols, excipient safety summaries, and regulatory-ready documentation that accelerates IND, NDA, and ANDA submissions without replacing lab validation.
by kody-w
Analyze your PLC code and ladder logic to identify logic errors, safety violations, and inefficiencies before they reach production. You'll get detailed diagnostics of control system failures, safety compliance verification against IEC 61131 standards, and optimization recommendations for automation sequences. This skill helps you prevent costly downtime, ensure worker safety, and improve system performance across manufacturing operations.
by kody-w
You can systematically identify production bottlenecks, forecast capacity constraints before they impact delivery, and optimize resource utilization across your manufacturing operations. By analyzing historical production data, demand forecasts, and resource availability, you'll generate actionable insights to maximize throughput and reduce downtime.
by kody-w
You systematically analyze workstations and work tasks for ergonomic hazards using industry-standard assessment methods (RULA, NIOSH, ISO 11228). You receive quantified risk scores, pinpointed hazard identification, and prioritized mitigation recommendations ranked by impact and feasibility. You can generate compliance-ready documentation and implement targeted interventions to reduce musculoskeletal injury risk.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-w